GlassScriptPhysician profile
Afsar Waraich
NPI 1497719975
$4,458.55
in general payments reported to CMS, 2019-2025
33 companies · $866 in 2025
The $866 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $887 · 2020: $426 · 2021: $18.53 · 2022: $624 · 2023: $646 · 2024: $991 · 2025: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,445 · Education: $58.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,445.36 |
| Education | $58.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,884.74 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $279.35 | 2019-2025 | Entyvio |
| Pfizer INC. | $216.06 | 2019-2025 | |
| Lilly USA, LLC | $205.31 | 2024-2025 | Omvoh |
| Janssen Biotech, INC. | $195.78 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $177.61 | 2019-2024 | Xifaxan, Plenvu |
| Qol Medical, LLC | $170.66 | 2019-2024 | Sucraid |
| Celgene Corporation | $156.46 | 2021-2024 | Zeposia |
| Daiichi Sankyo INC. | $122.92 | 2020-2024 | Injectafer |
| Ucb, INC. | $100.07 | 2019 | |
| Aimmune Therapeutics, INC. | $99.62 | 2024-2025 | Vowst, Zenpep |
| Celltrion USA INC. | $92.38 | 2024-2025 | Zymfentra, Vegzelma |
| Ironwood Pharmaceuticals, INC | $90.78 | 2019-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $73.45 | 2024-2025 | Voquezna |
| Shionogi INC | $70.62 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $58.45 | 2023-2024 | Hadlima |
| Neuraxis, INC. | $46.07 | 2025 | |
| Nestle Healthcare Nutrition INC. | $37.08 | 2022-2023 | |
| Allergan, INC. | $35.53 | 2019 | |
| Sanofi US Services INC. | $34.71 | 2024 | |
| Braintree Laboratories, INC. | $30.27 | 2020 | |
| Intercept Pharmaceuticals, INC. | $29.42 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $28.45 | 2022 | |
| Madrigal Pharmaceuticals | $27.68 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $26.89 | 2019-2020 | |
| Gilead Sciences, INC. | $26.06 | 2023 | |
| Mirum Pharmaceuticals, INC. | $23.92 | 2025 | Livmarli |
| Alfasigma USA, INC. | $23.57 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $23.51 | 2025 | Iqirvo |
| Ardelyx, INC. | $23.16 | 2025 | Ibsrela |
| Genzyme Corporation | $21.89 | 2024 | |
| Exact Sciences Corporation | $17.22 | 2023 | Cologuard Collection Kit |
| Endogastric Solutions, INC | $8.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Afsar Waraich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.